# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
– 358 enrolled and 223 patients currently on treatment across sites in the USA, Europe and Asia –– Brilaroxazine is generally w...
Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate o...
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical co...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains ...
Benchmark analyst Bruce Jackson reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Speculative Buy and maintains $17 pri...
Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate...